# DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment

Source: https://onco.cc/trials/nct07472517/  
OnCo record `nct07472517` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Atezolizumab, Carboplatin, Etoposide in small-cell lung cancer, run by Boehringer Ingelheim, now recruiting.

## Summary

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy is a phase 3 interventional study registered as NCT07472517 by Boehringer Ingelheim, with 670 participants planned, started 2026-04-13 and due to reach its primary completion in 2028-09-09. Interventions recorded: obrixtamig, atezolizumab, carboplatin, etoposide. Conditions listed: Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07472517
- Phase: 3
- Setting: DAREON ® -Lung-1: A Phase III Multi-center, Open-label, Randomised Trial of Intravenous Obrixtamig in Combination With Atezolizumab, Carboplatin, and Etoposide vs. Atezolizumab, Carboplatin, and Etoposide as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer
- Sponsor: Boehringer Ingelheim
- Enrolled: 670

## Sources

- ClinicalTrials.gov NCT07472517: https://clinicaltrials.gov/study/NCT07472517

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Etoposide](https://onco.cc/drugs/etoposide/)
- companies: [Boehringer Ingelheim](https://onco.cc/companies/boehringer-ingelheim/)

---
JSON: https://onco.cc/api/v1/entities/nct07472517.json